Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Eli Lilly and Company
Age
2–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Have acute T-cell lymphoblastic leukemia (T-ALL) or T-cell lymphoblastic lymphoma (T-LBL).
T-ALL or T-LBL participants with relapsed/refractory disease.
Have had at least 60 days between prior hematopoietic stem cell transplantation (SCT) and first dose of study drug.
Have a performance status of 0 to 2 on the Eastern Cooperative Oncology Group (ECOG) scale for adults.
Lansky score \>50% for participants \<16 years old.
Have adequate organ function.
Are at least:
* adult Phase 1 Part A and Phase 2: ≥16 years old at the time of screening
* pediatric Phase 1 Part B: 2 to \<16 years old
Men and women with reproductive potential: Must agree to use a reliable method of birth control during the study and for 3 months following the last dose of study drug(s) or country requirements, whichever is longer.
Females with childbearing potential: Have had a negative serum pregnancy test ≤7 days before the first dose of study drug and also must not be breastfeeding.
Are able to swallow capsules and tablets.
You may not be if
Have previously completed or withdrawn from this study or any other study investigating LY3039478 or other Notch inhibitors.
Have evidence of uncontrolled, active infection \<7 days prior to administration of study medication.
Have current or recent gastrointestinal disease with chronic or intermittent diarrhea, or disorders that increase the risk of diarrhea, such as inflammatory bowel disease.
Have active leukemic involvement of the central nervous system (CNS).
Clareo Health | A Study of LY3039478 in Combination With Dexamethasone in Participants With T-ALL/T-LBL
